No active 13F manager changed its position in PULSE BIOSCIENCES, INC. last quarter. Over the last 180 days, 3 insiders bought and none sold, a net +$13.5M in open-market trades.
The legs disagree, or only one of them leans.
Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Teplitsky Liane Rae | Chief Operating Officer | Buy (P) | 1K | $50K |
| Aug 31, 2026 | Teplitsky Liane Rae | Chief Operating Officer | Buy (P) | 1K | $50K |
| Aug 28, 2026 | Teplitsky Liane Rae | Chief Operating Officer | Buy (P) | 1K | $50K |
| Aug 26, 2026 | Teplitsky Liane Rae | Chief Operating Officer | Buy (P) | 1K | $50K |
| May 11, 2026 | Duggan Robert W | Director, 10% Owner | Buy (P) | 660K | $13.0M |
| May 11, 2026 | Laviolette Paul A | Chief Executive Officer, Director | Buy (P) | 15K | $295K |
| Feb 18, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 5K | $118K |
| Feb 17, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 20K | $473K |
| Feb 13, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 20K | $471K |
| Feb 12, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 20K | $467K |
| Feb 11, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 20K | $504K |
| Feb 10, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (S) | 20K | $470K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 3 | 0 | +$13.5M |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for PULSE BIOSCIENCES, INC.
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/PLES/capital-change-brief"
Use Arkolith's capital_change_brief for PULSE BIOSCIENCES, INC.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for PLES. Filings are public domain, sourced to SEC EDGAR.